Trial reportRMD open2026
Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label extension.
Trial report in RMD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis
A Multicenter, Open-Label Extension Study to Asses the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Study Participants With Active Axial Spondyloarthritis, Ankylosing Spondylitis, and Nonradiographic Axial Spondyloarthritis
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the sustained, long-term efficacy of bimekizumab in improving patient symptoms and health-related quality of life (HRQoL) in axial spondyloarthritis (axSpA) to 3 years.
methodsBoth BE MOBILE 1 (non-radiographic axSpA) and 2 (radiographic axSpA) comprised a 16-week double-blind, placebo-controlled treatment period and a 36-week maintenance period. From week 16, all patients received subcutaneous bimekizumab 160 mg every 4 weeks. At week 52, eligible patients could enter the open-label extension (OLE), BE MOVING and continue bimekizumab treatment. Here, we report pooled results for changes in spinal pain, morning stiffness (mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Q5 and Q6), physical function (Bath Ankylosing Spondylitis Functional Index (BASFI)), fatigue (BASDAI Q1 and Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue), sleep quality (Medical Outcomes Study Sleep (MOS-Sleep-R) Index II) and HRQoL (36-Item Short Form Questionnaire (SF-36) Physical Component Summary (PCS)/Mental Component Summary; Ankylosing Spondylitis Quality of Life (ASQoL)) to 3 years in the overall study population; for spinal pain and physical function, patient-level data are also reported.
resultsOf the 494/586 (84.3%) randomised patients who entered the OLE, 425/494 (86.0%) completed week 164. At week 164, patients reported mean improvements from baseline in total (-4.3) and nocturnal (-4.3) spinal pain, morning stiffness (-4.3), physical function (BASFI: -2.9), fatigue (BASDAI Q1: -3.5, FACIT-Fatigue: +9.7), sleep (MOS-Sleep-R Index II: +10.8) and HRQoL (SF-36 PCS: +12.3; ASQoL: -5.6). Rapid and sustained patient-level improvements to week 164 in spinal pain and physical function levels were observed.
conclusionsBimekizumab treatment led to rapid and sustained improvements in key patient symptoms and HRQoL to 3 years, emphasising its long-term value in controlling symptoms which profoundly affect patients' experience and daily lives. TRIAL REGISTRATION NUMBERS: BE MOBILE 1 (NCT03928704), BE MOBILE 2 (NCT03928743) and BE MOVING (NCT04436640).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.